MARKER THERAPEUTICS, INC. Lease, Cost
MARKER THERAPEUTICS, INC. (MRKR) reported Lease, Cost of $393.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2023-05-15
- MARKER THERAPEUTICS, INC. lease, cost for the quarter ending 2023-03-31 was $393.00K, a 35.26% decline year-over-year.
- MARKER THERAPEUTICS, INC. lease, cost for the quarter ending 2022-12-31 was $366.00K, a 39.30% decline year-over-year.
- MARKER THERAPEUTICS, INC. lease, cost for the quarter ending 2022-09-30 was $547.00K, a 7.76% decline year-over-year.
- MARKER THERAPEUTICS, INC. lease, cost for the quarter ending 2022-06-30 was $659.00K, a 18.95% increase year-over-year.
- MARKER THERAPEUTICS, INC. lease, cost for fiscal 2022 was $2.18M, a 5.59% decline from fiscal 2021.
- MARKER THERAPEUTICS, INC. lease, cost for fiscal 2021 was $2.31M, a 100.87% increase from fiscal 2020.
- MARKER THERAPEUTICS, INC. lease, cost for fiscal 2020 was $1.15M, a 180.24% increase from fiscal 2019.
- MARKER THERAPEUTICS, INC. lease, cost for fiscal 2019 was $410.00K.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-03-31 | $393.00K 10-Q · filed 2023-05-15 | $759.00K derived: sum of 2 quarters · filed 2023-05-15 | $1.31M derived: sum of 3 quarters · filed 2023-05-15 | $1.97M derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | $366.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $913.00K derived: sum of 2 quarters · filed 2023-03-22 | $1.57M derived: sum of 3 quarters · filed 2023-03-22 | $2.18M 10-K · filed 2023-03-22 |
| 2022-09-30 | $547.00K 10-Q · filed 2022-11-10 | $1.21M derived: sum of 2 quarters · filed 2022-11-10 | $1.81M 10-Q · filed 2022-11-10 | $2.42M derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-06-30 | $659.00K 10-Q · filed 2022-08-11 | $1.27M 10-Q · filed 2022-08-11 | $1.87M derived: sum of 3 quarters · filed 2023-05-15 | $2.46M derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-03-31 | $607.00K 10-Q · filed 2023-05-15 | $1.21M derived: sum of 2 quarters · filed 2023-05-15 | $1.80M derived: sum of 3 quarters · filed 2023-05-15 | $2.36M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $603.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $1.20M derived: sum of 2 quarters · filed 2023-03-22 | $1.75M derived: sum of 3 quarters · filed 2023-03-22 | $2.31M 10-K · filed 2023-03-22 |
| 2021-09-30 | $593.00K 10-Q · filed 2022-11-10 | $1.15M derived: sum of 2 quarters · filed 2022-11-10 | $1.71M 10-Q · filed 2022-11-10 | $2.21M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $554.00K 10-Q · filed 2022-08-11 | $1.11M 10-Q · filed 2022-08-11 | $1.62M derived: sum of 3 quarters · filed 2022-08-11 | $2.06M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $558.00K 10-Q · filed 2022-05-13 | $1.07M derived: sum of 2 quarters · filed 2022-05-13 | $1.51M derived: sum of 3 quarters · filed 2022-05-13 | $1.62M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $509.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $953.00K derived: sum of 2 quarters · filed 2022-03-17 | $1.06M derived: sum of 3 quarters · filed 2022-03-17 | $1.15M 10-K · filed 2022-03-17 |
| 2020-09-30 | $444.00K 10-Q · filed 2021-11-10 | $555.00K derived: sum of 2 quarters · filed 2021-11-10 | $640.00K 10-Q · filed 2021-11-10 | $751.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $111.00K 10-Q · filed 2021-08-10 | $196.00K 10-Q · filed 2021-08-10 | $307.00K derived: sum of 3 quarters · filed 2021-08-10 | $416.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $89.00K 10-Q · filed 2021-05-12 | $196.00K derived: sum of 2 quarters · filed 2021-05-12 | $305.00K derived: sum of 3 quarters · filed 2021-05-12 | $407.00K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $107.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $216.00K derived: sum of 2 quarters · filed 2021-03-09 | $318.00K derived: sum of 3 quarters · filed 2021-03-09 | $410.00K 10-K · filed 2021-03-09 |
| 2019-09-30 | $109.00K 10-Q · filed 2020-11-09 | $211.00K derived: sum of 2 quarters · filed 2020-11-09 | $303.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $102.00K 10-Q · filed 2020-08-10 | $194.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $92.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |